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Abstract
The success of genome-wide association studies has led to increasing interest in making
predictions of complex trait phenotypes including disease from genotype data. Rigorous
assessment of the value of predictors is critical before implementation. Here we discuss some of
the limitations and pitfalls of prediction analysis and show how naïve implementations can lead to
severe bias and misinterpretation of results.
Introduction
In many species, single nucleotide polymorphism (SNP)-trait associations have been
detected through genome-wide association studies (GWASs). In addition to the discovery of
trait-associated variants and their biological function, there is increasing interest in making
predictions of complex trait phenotypes from genotype data for individuals in plant and
Corresponding author: peter.visscher@uq.edu.au.
Web link:
Web applications for the equations in Box 2 are given at http://www.complextraitgenomics.com/software http://
pngu.mgh.harvard.edu/~purcell/plink/ http://www.complextraitgenomics.com/software/gcta/
NIH Public Access
Author Manuscript
Nat Rev Genet. Author manuscript; available in PMC 2014 July 15.
Published in final edited form as:
Nat Rev Genet. 2013 July ; 14(7): 507–515. doi:10.1038/nrg3457.
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
animal breeding, experimental organisms and human populations. These predictions are
based upon selections of SNPs (or other genomic variants) and estimation of their effects in
a discovery sample, followed by validation in an independent sample with known
phenotypes, and ultimately application to samples with unknown phenotypes (FIG 1).
The validation stage of SNP- prediction analysis will be the main focus of this Perspective.
Incorrect conclusions at this stage may lead to predictors that will not work as well as
inferred or, in the worst case, have no prediction accuracy at all. We organise our
Perspective into limitations and common pitfalls of prediction analysis. The limitations are
partly inherent given the nature of the trait or the data available. These are factors that users
should be aware of but mostly cannot change. The limitations also reflect use of sub-optimal
methodology that could be improved upon. The pitfalls are common mistakes in analysis
that can lead to over-estimation of the accuracy of a predictor or misinterpretation of results,
and we give examples from the literature where these have occurred. We give our opinion
on how best to avoid pitfalls in the derivation and application of SNP based predictors for
practical applications. There are many aspects of risk prediction that are outside the scope of
this article. They include a thorough treatment of the statistical methods that can be used in
the discovery phase1–7, the use of non-genetic sources of information to make predictions or
diagnosis, a full discussion about clinical utility of risk prediction in human medicine and a
discussion about ethical considerations for applications in human populations8.
Limitations of prediction analyses
Limitation 1: Prediction of phenotypes from genetic markers
Variation in complex traits is almost invariably due to a combination of genetic and
environmental factors. A useful quantification of the importance of genetic factors is the
heritability (h2), i.e. the proportion of phenotypic variation in a trait that is due to genetic
factors9 (BOX 1). Assuming that the estimated h2 is a true reflection of the population
parameter, the upper limit of the phenotypic variance explained by a linear predictor (R2)
based on DNA markers such as SNPs is h2 and a genetic predictor can thus never fully
account for all phenotypic variation. This upper limit is only achievable if all genetic
variants affecting the trait are known and their effects are estimated without error. In human
disease genetics, where ‘personalised medicine’ is actively being pursued, this limitation is
not well understood in our opinion and hence we have chosen to highlight it here, even
though it has been pointed out before10, 11.
Environmental risk factors can be added to the genetic predictor, to make a better predictor
of the phenotype. In practice not all environmental factors are identified (and some factors
classified as “environment” may simply be stochastic events12). For example, combining
SNPs and phenotypic predictors, such as body-mass-index and smoking, improved
prediction of age-related-macular degeneration, an eye disease in humans where age is a
major risk factor13. In some circumstances more accurate phenotyping, including the use of
repeated measures, can lead to a more heritable trait. In general, expectations need to be
adjusted accordingly for the application of phenotype or disease prediction in humans.
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Unlike the deterministic genetic tests for fully penetrant Mendelian disorders, genetic
predictions for complex traits will be probabilistic and the value may only be incremental in
clinical decision making. The value of genetic risk prediction may be at a group level rather
than individual level. For example, from a risk predictor for type 1 diabetes (T1D), created
from risk variants known up to 2011, a risk group comprising the top ranked 18% of
individuals would need to be monitored in order to capture 80% of future cases, yet because
T1D is not common (prevalence 0.4%) the probability of disease for individuals in this risk
group is still less than 2%14. Nonetheless, cost-effective public health strategies could result
from use of genetic predictors to identify high-risk strata where disease prevention
interventions should be focussed15, 16. In agriculture, genetic risk prediction is geared
mostly towards selection of breeding stock based on estimates of additive genetic values
(‘estimated breeding values’) in the parent generation with the aim of eliciting changes in
the phenotype of the of the offspring generation on average. That is, the impact of genetic
prediction is naturally at the level of a group rather than an individual.
Limitation 2: Variance explainable by markers
The SNPs included in the genome-wide SNP chips used for identifying SNPs associated
with complex traits are typically not the causal variants for a phenotype – more likely they
may have an association with the trait because they are in linkage disequilibrium (LD) with
one or more causal variants. Since the SNPs on SNP chips are chosen because both their
alleles are common they cannot be in complete LD with a causal variant with one rare allele.
If the variation generated by the causal variants is completely explained by the genotyped
SNPs, then the SNPs potentially can explain all the genetic variation in the trait (i.e. ,
where  is defined as the genetic variation captured by the SNPs, or markers). Sometimes
(e.g.17)  is referred to as "narrow-sense heritability", however in our opinion, the term
"narrow-sense heritability" should be reserved as the definition of the total additive genetic
variance, that is h2 (see refs9, 18).
If a genetic variant is associated with fitness, selection will drive one allele to low
frequency19–21. This is the case even for traits without an obvious connection to fitness. The
larger the effect of a SNP on a fitness the lower the frequencies of the causal alleles are
expected to be22, 23. For example, individual mutations causing severe intellectual disability
in humans are rare24, 25. Therefore, in practice, the SNPs identified as associated in the
discovery population are unlikely to explain all genetic variation (i.e,  < h2) since
contributions to the variance by rare variants may not be tagged by the genotyped
SNPs26–28. For example, for both height and schizophrenia h2 ~ 0.7–0.8 and  ~ 0.5 for
height26 and 0.2–0.3 for schizophrenia29, 30.
The difference between the variance explained by genome-wide significant (GWS) SNPs
( ) and heritability estimate from family studies (h2) has been called the “missing
heritability” and the difference between  and  the “hidden” heritability, so that the
difference between  is the “still missing heritability”, i.e.,  <  < h2. The still
missing heritability may simply reflect genomic variants not well tagged by SNPs. In
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livestock populations, when missing heritability is defined in this way, little is missing with
up to 97% of the heritability captured by common SNPs31, 32, probably because the smaller
effective population size leads to long range LD and hence even rare alleles can be predicted
by a linear combination of SNPs in LD with the causal variant. Even in dairy cattle however,
traits that could reasonably be assumed to be under strong natural selection, such as fertility,
have greater missing heritability31. Moreover, when the SNPs are fitted together with a
pedigree as much as half of the genetic variance is explained by the pedigree and not the
SNPs33. The simplest explanation is that in livestock as in humans some causal variants are
rare and in poor LD with the SNPs.
With the advances in whole genome sequencing technologies, causative mutations will be
present in the data and the proportion of variation that can be captured by the sequence data
is expected to approach h2. In principle, known rare risk variants, if identified, can be
included in the predictor in the same way as common variants; cumulatively their
contribution may be important. Their importance can be assessed by the proportion of
variation they explain. Both the ability to detect an association between a trait and a SNP,
and the value of including the SNP in a predictor, depend on the proportion of variance the
SNP explains. For example, a rare variant with a frequency of 1/1000 in the population and
a relative risk for a disease of 5 will increase the risk of disease by 5-fold for 1 in 1000
people (so from 1% to 5% for a disease with a prevalence of 1%), but such an increase in
risk can also be achieved by the cumulative effect of multiple common variants with smaller
effect size. The contribution of rare variants can be included into a predictor by grouping
them into defined classes of genes31, 32, or by incorporating prior knowledge of functions34.
Limitation 3. Errors in the estimated effects of the markers
The effects of SNPs on a trait must be estimated from a sample of finite size and so the
effects are estimated with some sampling error. If there were only a few loci that affected a
trait, it would be possible to estimate their effects quite accurately, but most complex traits
are controlled by a very large number of largely unknown loci35. Therefore the discovery
stage of estimating the prediction equation may involve a genome-wide panel of millions of
SNPs. The true effects of most SNPs are small and so the accuracy with which these effects
are estimated is low unless a very large discovery sample is used. The correlation between
phenotype and a predictor that uses all SNPs simultaneously in a random mating population
can be expressed as a function of effective population size (or the effective number of
independent chromosome segments which is a function of effective population size),
heritability and the size of the discovery sample (Equation 1, BOX 1)36–38. Specifically,
SNP effects will be better estimated when the sample size of the discovery cohort increases
(Figure BOX1); estimated or predicted effect sizes of rare variants will be difficult to verify
even with large sample sizes.
Limitation 4: Statistical methods in the discovery sample
The least squares prediction or ‘profile scoring’29 method is commonly used for prediction
of genetic risk. Although simple to apply it does not have desirable statistical properties and
an arbitrary p-value threshold is used for the selection of SNPs that go in the predictor.
Moreover, estimation of SNP effects one at a time is not an optimal approach1, 39–44. This is
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because SNP effects are correlated and accounting for LD in the profile scoring method
requires SNP selection on arbitrary thresholds. Methods that model the distribution of SNP
effects40 and the correlation between SNPs in the presence of single as well as multiple
causal variants will be more accurate1, 39–43, 45. In human applications, sometimes only
genome-wide significant SNPs are included in the predictor15, 46–49, yet greater accuracy
results from the use of less stringent thresholds1, 37, 40 and in animal and plant breeding it is
typical to use all available SNPs. Better SNP estimation methods exist and are used in plant
and animal breeding1, 2, 37, 44, 50 and such methods have been proposed for applications to
human data1, 43. They rely on prior assumptions about the distribution of SNP effects in the
genome, and use all data simultaneously. Such Bayesian methods have also been applied to
other species51, and related methodologies derived in computer science have been applied to
disease data in humans4, 52. Ignorance can’t be bliss in this context and it must be best to use
all available genetic and phenotypic information simultaneously. It is outside the scope of
this Perspective to discuss these methods in more detail.
Pitfalls of the analysis
Pitfall 1: Validation and discovery sample overlap
If the correlation (R) between a phenotype and a single SNP in the population is zero (that
is, the SNP is not associated with the trait), the expected value of the squared correlation
(R2) estimated from a sample of size N is 1/(N-1), or approximately 1/N if N is large. Hence,
a randomly chosen ‘candidate’ (but not truly associated) SNP explains 1/N of variation in
any sample. Usually 1/N is small enough not to worry about. However, a set of m
uncorrelated SNPs that have nothing to do with a phenotype of interest would, when fitted
together, explain m/N of variation (due to the summing of their effects). For example, a set
of 100 independent SNPs when fitted together in a regression analysis in a discovery sample
of Nd = 1000 would, on average, explain R2 =10% of phenotypic variance in the discovery
sample under the null hypothesis of no true association.
When the number of SNPs in the predictor is large and the sample size is small, the
discovery R2 can be very high by chance and can be a gross over-estimation of the true
variance explained by the predictor when applied in an independent sample. Also, the
expected R2 in the validation sample for a set of SNPs selected from a discovery sample but
with the effect sizes of the SNPs re-estimated in the validation sample is ~1/Nv, with Nv the
validation sample size. Therefore, to estimate the R2 of a prediction in a new sample, a
prediction equation is estimated in the discovery sample and is tested, without re-estimating
the regression coefficients, in the validation sample (Box 2). Applying the incorrect
validation procedure results in over-estimation of the accuracy of the prediction (or over-
fitting). An example of where over-fitting occurs is when testing the prediction in the
discovery sample, i.e., the same data are used to estimate the effect of SNPs on phenotype
and to make predictions53, 54 . We illustrate the overlap pitfall with examples in dairy cattle,
Drosophila and human populations (FIG 2a-c). . For example, in a GWAS on ~150
sequenced inbred lines of Drosophila54 in which this was done the authors concluded that
6–10 SNPs selected from > 1M SNPs together explained 51–72% of variation in the lines
(depending on the trait analysed). However, a cross-validated Bayesian prediction analysis
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using all genetic markers on the same data found that only 6% of phenotypic variation could
be explained by the predictor51.
A less obvious mistake is to select the most significantly associated SNPs in the entire
sample and to use these to estimate SNP effects and test their prediction accuracy in the
discovery and validation sets55. In this case the variance explained by the SNPs when
applied in the validation sample is inflated. It creates bias and misleading results because the
initial selection step of the SNPs is based upon there being a chance correlation between
these SNPs and the entire sample, so also between the SNPs and any sub-sample. A
prediction equation based on these SNPs will appear to work in the validation sample but
not in a genuinely independent sample. Cross-validation analysis after the initial set of
SNPs has been selected from the entire sample does not mitigate this bias. The pitfall of
SNP selection from discovery and validation samples occurred in a recent study reporting a
genetic predictor of autism56. SNPs putatively associated with autism in multiple biological
pathways were selected based upon p-values from GWAS in the entire data set. Model
selection was subsequently applied using cross-validation to narrow down the number of
SNPs. The authors did follow up with an independent validation sample, and the prediction
accuracy was reduced.
A variation on this pitfall is when a proportion of individuals in the validation sample are
also in the discovery sample and then the bias is proportional to the fraction of the validation
samples that was also in the discovery set (see BOX 2). In practice it might be difficult to
ascertain if any of the validation individuals were also in the discovery set, in particular if
there are only summary statistics (i.e., estimates and standard error of SNP effect and allele
frequencies) available, particularly from public databases. We use cattle data44 to illustrate
the inflation in variance explained by a SNP predictor when the validation sample is
included in discovery steps (Fig 2c)
The remedy to this pitfall is to use external validation. In some cases independent data sets
are not available in which case internal cross-validation is the only option. In cross-
validation it is important to avoid the pitfall of updating the predictor based on results
derived from the validation sample, hence losing the independence of discovery and
validation samples that the strategy has set out to achieve57. Overlap in samples can be
checked as part of quality control (QC) of the prediction pipeline, by estimating pairwise
relatedness using SNP data, but this requires access to full genotype data from both
discovery and validation samples. There are many software tools that can do this, including
PLINK58 and GCTA59.
Pitfall 2: The validation sample
If the validation sample is more closely related to the discovery population than to the target
population, then the prediction accuracy will be over-estimated. In humans, a polygenic
prediction analysis of height in 5,117 individuals from the Framingham Heart Study (FHS;
original and offspring cohorts only) reported a prediction R2 of 0.25 using 10-fold cross-
validation when including all individuals in the analysis60. However, because FHS includes
many related individuals, the authors repeated the analysis restricting the 10-fold cross-
validation samples to individuals with no known close relatives (parent-offspring, sibling, or
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half-sib) in the data set based on pedigree information. In this restricted analysis, the
prediction R2 decreased to 0.15. We caution that cryptic relatedness can still inflate
prediction accuracy even when known close relatives are excluded. To demonstrate this, we
conducted a polygenic prediction analysis of height using 7,434 individuals from the FHS
SHARe data61 (BOX 3). Our results demonstrate that cryptic relatedness, beyond the close
relatives inferred from pedigrees, can inflate prediction accuracy relative to the prediction
accuracy that could be achieved in an independent validation sample.
The remedy of the pitfall described here is to use conventionally unrelated individuals (in
discovery and validation stages). Relatedness can be estimated from SNP data58, 59 and so
close relatives can be excluded based upon observed data. More generally, the validation
population should be representative of the population in which the predictor will ultimately
be applied. In populations with small effective population size, such as some breeds of
livestock, all individuals are related. This does not invalidate the prediction but it does mean
that the same prediction accuracy cannot be expected when the prediction equation is
applied to another population that is less closely related to the discovery population62.
Sometimes the validation population differs from the application (target) population in that
it is much more genetically diverse. For example, the validation (and possibly discovery)
population might include a diverse set of lines of animals or plants. A prediction equation
may work well in this population but less well in an application population that is less
diverse such as commercial strains of a crop62.
Pitfall 3: Population stratification similarity
Another way in which prediction accuracy can be inflated is if the discovery and validation
samples contain similar patterns of population stratification and the eventual target
population is not similarly stratified. For example, this could occur if discovery and
validation samples are independently sampled from a stratified population such as European
Americans63. The question of whether this inflation should be viewed as a pitfall depends on
the ultimate goal of the analysis. If the goal is to conduct prediction in European Americans,
it is entirely appropriate to leverage ancestry information to the fullest extent possible, and
this inflation is not a pitfall (because discovery, validation and target samples are similarly
stratified). On the other hand, if the goal is to assess the prediction accuracy that could be
achieved using less structured application populations, then this inflation is a pitfall. As an
example, we show that population stratification was inflating prediction accuracy in the FHS
analysis (See BOX 3 for details). A more serious problem is when there is confounding
between ancestry and disease status both in discovery and validation case-control samples,
because such spurious association can lead to a predictor of ancestry rather than one of
disease. It was recently suggested that the aforementioned predictor of autism56 suffers from
this pitfall64.
A practical remedy to problems associated with population stratification is to fit ancestry
principal components in the analysis of discovery samples. We note that differential bias
between cases and controls65 can also lead to spurious prediction R2 if discovery and
validation samples exhibit the same differential bias, as could occur when using 10-fold
cross-validation. A remedy for differential bias is to perform stringent quality control and/or
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to validate in a completely independent sample, in lieu of 10-fold cross-validation. One QC
step that can be done is to use the genotyped SNPs that are in the predictor and quantify the
estimated relatedness between the application sample and the discovery and validation
samples, for example in a principal component analysis (PCA)66 or related methods67. If the
application sample is an outlier on the PCA then the prediction accuracy in the target may be
less than expected from the validation procedure.
Pitfall 4: Expectation of equality of R2 and 
Sometimes called the SNP- or chip-heritability, an unbiased estimate of the variance
explained by markers  is achieved by correlating phenotypic similarity between pairs of
individuals with their SNP-based genotypic similarity26, 59, 65. In human populations, the
SNP-heritability is broadly between one-third and one-half of total heritability for traits
studied to date28, 35, 68. A prediction of phenotype based upon the same set of SNPs would
achieve an R2 =  only if the individual SNP effects were estimated without error27. For
example, when a multiple-SNP predictor that used the ‘profile scoring’ method was used for
height61, it achieved an R2 of 10–15% in out-of-sample predictions. Yet Yang et al (2010)26
estimated that all the SNPs together would explain 40–50% of phenotypic variance if their
effects were estimated without error. These results are not inconsistent when the error
associated with the estimate of each SNP effect is appreciated.
With ever-larger sample sizes, the size of the error terms in the SNP effect estimates will be
reduced, and the two statistics will converge to the same value. However, simulations for
human populations suggest that the improvement in trait prediction as sample size increases
depends on the genetic architecture of the trait, in particular how many variants there are
with tiny effect sizes, and that for most common complex genetic diseases the improvement
will be slow and modest even when common SNPs account for a large proportion of
heritability of the traits17. Hence, for applications in human populations to achieve
meaningful and accurate predictions, big data are key and sample sizes of hundreds of
thousands needed and such data sets are starting to become achievable.
Conclusions
We highlighted what we believe are limitations to genetic risk prediction as well as the most
important pitfalls to befall researchers and discussed how these can be avoided. Most
problems occur in the validation stage, when data are not fully independent to those in the
discovery phase, but care is also needed to ensure that the discovery and validation samples
are representative of the population in which the predictor will be applied. Genomic
prediction is already having a major impact in livestock selection programmes37 and has
great potential for applications in plant breeding, preventative medicine strategies and
clinical decision making. However, there are fundamental limitations to the predictive
ability of a genetic predictor (see limitations 1 and 2) and so it is important that expectations
are realistic and that the accuracy of genetic predictors are fairly evaluated. As sample sizes
increase, predictors of genetic risk will have greater clinical utility, particularly in terms of
identification of population strata at increased risk of disease as opposed to accurate
predictive diagnosis for individuals.
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Glossary
Heritability The proportion of phenotypic variance attributable to additive
genetic variation.
Estimated
Breeding Value
An estimate of the additive genetic value for a particular trait that an
individual will pass on to descendants.
Linkage
Disequilibrium
The non-random association of alleles at different loci.
Effective
population size
The number of individuals in an idealized population with random
mating and no selection that would lead to the same rate of
inbreeding as observed in the real population.
Polygenic
prediction
analysis
Any analysis method that predicts genetic risk or breeding values
based on the combined contribution of many loci.
Profile scoring A polygenic prediction method for prediction of genetic value or
risk for each individual (a “profile”) in a validation sample
generated from the sum of the alleles they carry weighted by the
association effect size estimated in a discovery sample.
Independent SNPs Independent, uncorrelated SNPs are in linkage equilibrium.
Although the effective number of independent markers in standard
GWAS chips has sometimes been assumed to as large as 200,000
(e.g. ref17), we believe that 60,000 is a more appropriate value, as
analyses of LD29, genomic inflation factors69 and eigenvalues from
principal components analysis70 have consistently produced
estimates close to 60,000 in European populations. Predictions from
theory, based upon random mating populations of a given effective
size and for given genome length, also come to this number36. Thus
the appropriate value for M is approximately 60,000.
Independent
sample
In the context of risk prediction an independent sample means a
sample from the same population but excluding individuals that are
closely related. Necessarily, the individuals in different samples
from the same population will share common ancestors, and indeed
this distant sharing underpins the efficacy of a risk predictor.
Cross-validation To test the validity of a prediction in the absence of an independent
external validation sample, the sample is divided into k independent
subsets (balanced with respect to case-control status in disease
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data). Each of the k subsets is used in turn as a validation sample for
a predictor derived from the remaining k-1 subsets.
Ancestry
principal
components
Principal components derived from the genome relationship matrix
that account for the genetic substructure of the data. In case-control
studies these principal components can reflect genotyping artefacts
such as plate, batch and genotyping centre that could be confounded
with case-control status.
Cryptic
relatedness
Cryptic relatedness is when a sample is thought to comprise
unrelated individuals based on record pedigree relationships but in
fact includes close relatives, for example 2nd cousin or closer.
Conventionally
unrelated
Individuals from that are not closely related, for example more
distantly related than 3rd cousins
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Box 1. Quantifying phenotypic variation explained by SNPs
Quantitative traits
The proportion of phenotypic variance explained (R2) by a predictor of a quantitative trait
formed using estimated effects of all markers depends on the number (M) of independent
measured genomic variants (e.g., SNPs) associated with the trait, the proportion of the
total variance they explain ( ), and the sample size in the discovery sample
(Nd)27, 36, 38. If all marker effects are assumed to come from the same normal
distribution, then approximately
[Equation 1]
Equation 1 holds regardless of the genetic architecture of the trait, but we note that the
(least squares) predictor may be far from optimal.  is usually less than the heritability
estimated from family studies and is sometimes called the SNP-heritability or chip-
heritability, estimated, for example, using GCTA52. Equation 1 is from the supplement of
ref38; when R2 is small it can be ignored from the denominator, otherwise the quadratic
in R2 can be solved. The graph below shows that the sample size must be large in order to
achieve a high R2. If the distribution of marker effects sizes is markedly non-normal,
with some large effects and many very small or zero effects, and if knowledge of this
distribution is used in estimating SNP effects then higher R2 can be achieved61.
In this article we use R2 at the statistic to report efficacy of a predictor or R, the
correlation between phenotype and predictor or accuracy. The sign of the correlation is
important for interpretation of the predictor. In livestock, genetic predictors have been
used for decades (based on pedigree data prior to the availability of genotypic data) and
accuracy (RG,Ĝ) is traditionally used to evaluate utility. RG,Ĝ is the correlation between
true and estimated genetic value (the predictor, which is an estimate of the combined
value of all genetic loci). Since , the RG,Ĝ statistic quantifies the efficacy of a
genetic predictor relative to the best possible genetic predictor.
Disease traits
For disease traits, Nagelkerke’s R2 ( ) has been used in profile scoring analyses,
following Purcell et al29.  is an R2 measure in binary (0–1) outcome data. Application
is usually in case-control validation samples, where the proportion of cases is much
higher than in the population. Alternatively, the area under the receiver operator curve
(AUC) is reported74–76, a statistic with a long tradition of use in determining the efficacy
of clinical predictors. AUC has a desirable property of being independent of the
proportion of cases in the validation sample; one definition of AUC is that a randomly
selected case is ranked higher by the predictor than a randomly selected control. A new
statistic reflecting variance explained on the liability scale ( ), which it can be related to
other statistics such as  and AUC11, has been proposed77. Like any estimate on the
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liability scale, calculation of  requires specification of disease prevalence in the
population, but allows direct comparison of the variance explained by the predictor to
estimates of heritability from family data and estimates of SNP-heritability from genome-
wide SNP data.
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Box 2. Quantifying prediction accuracy for pitfall 2
When discovery and validation samples are independent
When m SNPs have been selected from a discovery sample, a simple linear predictor in
the validation sample is , with xi = 0,1 or 2 reference alleles of a SNP and bõi the
estimated effect size from the discovery sample. In this article we do not concern
ourselves with how bõi is estimated – there are simple least squares and more complex
Bayesian estimation methods that have been described elsewhere1, 41, 42. We also restrict
ourselves to linear (additive) models. Given a multi-SNP predictor (ŷ), the validation
step is to quantify how much of the variation in trait y is explained by the predictor ŷ. A
regression of y on ŷ fits only a single covariate so the R2 expected by chance is only
1/Nv, where Nv is the validation sample size. If the validation sample is drawn from the
same population as the discovery sample, then a value of R2 > 1/Nv is evidence for real
predictive ability of the predictor. (Software tools output an adjusted R2 that corrects for
the R2 expected by chance). Hence the sample size in the validation stage does not have
to be large to reject the null hypothesis of no association, H0: ũ2 = 0, where ũ2 true value
of R2 in the population. The standard error (SE) of R is approximately  if ũ is
very small, and more generally . In terms of R2, its SE is approximately
 with ũ small. A general and a more complicated exact equation was given by
Wishart (1931)77. Using the exact equations, if ũ2 is 1% or 10%, then SE(R2) for Nv =
100 is 1.9% or 5.6% and for Nv = 500 it is 0.8% and 2.5%.
When discovery and validation samples are the same
In the supplementary material we derive an approximation of R2 (verified by simulation)
when there is no correlation in the population between SNPs and phenotypes, but when m
“associated” SNPs are identified from the same sample (of size N) in which they are
validated as a predictor. The relationship between R2 and N, dependent on m and
assuming M = 100,000 independent genomic variants associated with the phenotype is
plotted below in which m SNPs (m = 10, 100 or 1000) are selected after association
analysis of M = 100,000 uncorrelated SNPs in a sample of unrelated individuals and
applied as a predictor back into the same sample, when there is no correlation between
SNPs and phenotypes. In genome-wide association studies M is large so overestimation
of R2 occurs even for big sample sizes.
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When validation sample overlaps with the discovery sample
If some of the samples in the validation cohort are also in the discovery set then this can
create spurious results. For the samples that overlap, the expected R2 between predictor
and outcome is the same as in the entire discovery sample, because those samples are just
a random sample from the discovery cohort. If the proportion of samples in the discovery
set that are also in the validation cohort is q, then the expected squared correlation
between predictor and outcome in the entire validation cohort is approximately q*R2 +
(1-q)/Nv, with R2 the (spurious) accuracy derived in the supplementary material (see
previous section). The important result is that if samples overlap it is not the proportion
of those samples in the discovery cohort that matters but it is the proportion of the
validation samples that is also in the discovery cohort that determines false accuracy.
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Box 3. Using the Framingham Heart Study (FHS) to illustrate pitfalls of
validation
The FHS is a large cohort study of individuals and their family members measured for a
wide range of traits (particularly related to cardiovascular disease) and with genome-wide
genotypes. A polygenic prediction analysis of height60 showed that including known
related individuals in the analysis inflated R2 (from 0.15 to 0.25) To investigate if genetic
relatedness can still inflate prediction accuracy even when known close relatives are
excluded, we conducted a polygenic prediction analysis of height using 7,434 individuals
from the FHS SHARe data61. We obtained a prediction R2 of 0.13 using 10-fold cross-
validation when restricting to individuals with no known close relatives in the data set
based on known pedigree information. (We fit markers individually whereas in the
original study60 markers were fitted simultaneously via a Bayesian random effects
model, thus it is expected that a slightly higher R2 of 0.15 was reported). We repeated the
analysis restricting to individuals with pairwise relatedness estimated from the SNPs of
less than 0.40, 0.20, or 0.05, and obtained prediction R2 of 0.08, 0.06 and 0.06,
respectively, demonstrating the importance of using the genotype data to identify
relatives rather than accepting recorded family relationships.
We investigated whether population stratification was inflating prediction accuracy in our
FHS analysis, as the prediction R2 of 0.06 was much higher than would be expected from
theory36 or from empirical data on much larger sample sizes61. When repeating the
analysis using a height phenotype that was adjusted for 10 eigenvectors66 of the SNP
derived relationship matrix, once again restricting to individuals with pairwise
relatedness less than 0.40, 0.20, or 0.05, we obtained prediction R2 of 0.06, 0.01 and
0.00, respectively, which were smaller than the prediction R2 obtained using unadjusted
height. The bulk of the reduction came from correcting for the top eigenvector,
representing northwest European vs. southeast European ancestry63, which is strongly
correlated to height (R2=0.05 in FHS data, consistent with other studies78, 79). Thus,
consistent with theory, polygenic prediction analyses of a few thousand unrelated
individuals that do not benefit from population stratification will attain a low prediction
R2 (<0.01). The results of these analyses are summarised in the graph below.
Wray et al. Page 19
Nat Rev Genet. Author manuscript; available in PMC 2014 July 15.
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
Wray et al. Page 20
Nat Rev Genet. Author manuscript; available in PMC 2014 July 15.
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
NIH-PA Author M
anuscript
Figure 1.
Flowchart of SNP-based prediction analysis. There are three stages for the development of a
risk predictor – discovery, validation and application. At each stage data is needed as an
input, a process is applied to the data and a result is generated.
a. At this stage effect sizes estimated from combined discovery and validation samples can
be used.
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Figure 2. Examples of the overlap pitfall: non-independence of discovery and validation samples
a) Human: High R2 can be achieved by chance particularly when sample size is small.
We simulated GWAS data based upon real human genotype data under the null hypothesis
of no association. We used data of 11,586 unrelated European Americans genotyped on
563,212 SNPs 71–73. We randomly sampled N individuals and selected top SNPs for height
at p < 10−5 (red bar) and p < 10−4 (blue bar) to predict the phenotype in the same data. We
also performed association analysis for real height phenotype in 10,000 individuals and
selected top SNPs at p < 10−5 (green bar) and p < 10−4 (purple bar) to predict height
phenotype in the same sample. The graph shows the mean prediction R2 over 100 simulation
replicates. Error bar: standard error of the mean. The number on top of each column is the
mean number of selected SNPs over 100 simulation replicates.
b) Drosophila: An example, illustrating bias when selecting the top SNPs. We downloaded
genotype data of the Drosophila Genetics Reference Panel and simulated phenotypes under
the null hypothesis, i.e., random association between each of the > 1 million SNPs and
phenotype. We repeated the GWAS analysis reported in54, selecting the top 10
independently associated SNPs and predicted the phenotypes of the lines using these 10
SNPs. Since in the simulated data there are only random associations between SNP and
phenotype any prediction power is false and result of over-fitting. By chance, the top SNPs
(in terms of test statistic) explain 57% (R2=57%) of the phenotypic variance between the
inbred lines, from a linear regression of phenotype on predictor. Both phenotype and
predictor have been standardized to normal distribution z-scores (mean of zero and standard
deviation of one).
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c) Dairy Cattle: The impact of leaving the validation cohort in the discovery set, either at
both SNP selection (GWAS) and SNP effect estimation stages, or at the effect size
estimation stage only. Data shown are from 2,732 bulls with ~500K SNPs phenotyped for
average milk yield of their daughters’ milk production. The bulls were split into a discovery
sample (bulls born during or before 2003), Nd = 2,458, and a validation sample (bulls born
after 2003) of Nv= 274.
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